Authors:

Tianshu Liu, Yulong Zheng, Yi Feng, Yiyi Yu, Wei Li, Cheng Xiao, Jiong Qian, Chenyu Mao, Ning Li, Michael Shi, Chuan Qi, Lei Chen, Steven Yu, Jenny Yao, Lingmin Lu, Jianming Wang

Department of Medical Oncology, Zhongshan Hospital, Fudan University; Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine; Suzhou Transcenta Therapeutics Co., Ltd

Background:

• Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are key players in tumor angiogenesis signaling pathway. VEGF and VEGFR inhibitors have demonstrated clinical benefit in multiple cancer and eye diseases.

• MSB0254 is a humanized vascular endothelial growth factor receptor 2 (VEGFR-2) monoclonal antibody which inhibits angiogenesis induced by either VEGF-A or-C.

• This is a phase I study to evaluate MSB0254’s safety, tolerability and PK profiles, as well as preliminary anti-cancer activities in Chinese patients with advanced solid tumors.

Methods:

This FIH phase I study (NCT04381325) comprises a dose escalation phase and an expansion phase. Patients with locally advanced or metastatic solid tumor and have failed or intolerable to prior standard therapies will be enrolled.

Conclusions and Future Directions of Research:

MSB0254 demonstrated a manageable safety profile and preliminary antitumor activity in patients with advanced solid tumors. 16mk/kg Q2W and 20 mg/kg Q3W were recommended as RP2D.

The study of MSB0254 on selected types of tumor warrants further investigation.